Blue Wave Therapeutics is pleased to announce the appointment of Patrick Burgermeister as Chief Business Officer (CBO), effective 15 September 2026.
Patrick brings more than 25 years of experience across biotechnology, the pharmaceutical industry, venture capital and company building, with extensive expertise in business development, partnering, licensing, investment and corporate strategy.
He led business development and partnering activities at Apeiron Biologics, including transactions and strategic partnerships, and spent 10 years with BioMedPartners as a Partner, working closely with early-stage therapeutics companies and gaining extensive board and investment experience across the biotech sector.
Patrick combines a scientific background in molecular biology from the Biozentrum, University of Basel, with a business degree from the University of St. Gallen (HSG). As CBO, Patrick will work closely with Blue Wave’s leadership team to drive our business development and partnering strategy, support financing and corporate development activities, and further strengthen our relationships across the biotechnology, pharmaceutical, radiopharmaceutical and investment communities.
Patrick joins Blue Wave at a key stage in the Company’s development as we advance our innovative platform for the targeted delivery of alpha-emitting radionuclides and our lead program in recurrent glioblastoma, while preparing for the next phase of growth.
We are delighted to welcome Patrick to Blue Wave and very much look forward to working together.
